Johnson & Johnson vs Nutrien Ltd — how do they compare? Johnson & Johnson trades at $261.44 (market cap $618.09B), while Nutrien Ltd trades at $67.48 (market cap $33.31B). The key difference: Johnson & Johnson is far larger — about 18.6× Nutrien Ltd's market cap, and Nutrien Ltd pays the higher dividend (3.15%). Which is the better fit depends on your goals — on Pluang, investors hold Johnson & Johnson for 129 Days and Nutrien Ltd for 59 Days on average.
| JNJ | NTR | |
|---|---|---|
Market Cap | $618.09B | $33.31B |
Volume | 6,050,983 | 1,330,729 |
Sector | Health | Basic Materials |
52-Week High | $278.43 | $83.94 |
52-Week Low | $186.00 | $53.64 |
Typical Hold Time | 129 Days | 59 Days |
Enterprise Value | $646.37B | $45.11B |
Dividend Yield | 2.09% | 3.15% |
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $256.48, down 0.76% today, with a bearish technical signal despite recent earnings beats. The stock shows strong fundamentals with 28.45% net profit margin and consistent revenue growth to $94.19B in 2025. Analyst consensus remains positive with a $286.53 price target, though technical indicators show resistance at $258 and support at $253. Recent news highlights pipeline strength including Icotyde's $4.5B peak sales potential (Bank of America, 2026-09-29).
JNJ presents a compelling long-term investment with diversified healthcare exposure and dividend stability, though near-term technical weakness and patent cliff concerns warrant caution. The 52.5% buy rating from analysts reflects confidence in innovation pipeline, while debt-to-asset ratio increase to 24.06% merits monitoring. Upside potential exists if Q3 earnings beat expectations on October 13.
Nutrien (NTR) trades at $69.87, down 0.14% with a bearish technical signal despite positive analyst sentiment. The company shows improving fundamentals with 2025 revenue of $26.89B and net income of $2.27B, representing an 8.44% margin. Recent earnings show mixed results with Q1 2026 beating expectations but Q2 2026 missing estimates. Cash flow trends indicate operational strength with $4.01B from operations in 2025, though net cash flow remains negative. The stock faces headwinds from fertilizer industry challenges but benefits from strong potash demand and cost discipline.
NTR presents a moderate buy opportunity with 60.61% analyst buy ratings and $76.14 consensus price target offering 9% upside. Key catalysts include November 2026 Investor Day and structural gas arbitrage benefits, while risks involve fertilizer price volatility, geopolitical supply disruptions, and sulfur cost pressures. The company's North American nitrogen assets provide competitive advantage, but investors should monitor agricultural cycle trends and input cost management.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →Created in 2018 as a result of the merger between PotashCorp and Agrium, Nutrien is the world's largest fertilizer producer by capacity. Nutrien produces the three main crop nutrients--nitrogen, potash, and phosphate--although its main focus is potash, where it is the global leader in installed capacity with roughly 20% share. The company is also the largest agricultural retailer in the United States, selling fertilizers, crop chemicals, seeds, and services directly to farm customers through its brick-and-mortar stores and online platforms.
Read more on NTR →